Metabolic Syndrome and Pancreatic Cancer: Linking Insulin Resistance, Inflammation, and Carcinogenesis
Diagnostics · 18.08.2026 · 16 (16) · 2616
DOI: 10.3390/diagnostics16162616 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 18.08.2026. Verfasst von Rahela Borbei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, 4th Medical Discipline, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania. Die Arbeit nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic syndrome (MetS) is a composite classification defined by heterogeneous combinations of cardiometabolic abnormalities. Several components have been associated with pancreatic cancer (PC), but studies often conflate long-term metabolic exposure, tumor-related prediagnostic metabolic change, and prognosis after diagnosis. This review critically evaluates these three settings. This narrative review searched PubMed, Scopus, and Web of Science through April 2026, prioritizing meta-analyses, prospective cohorts, Mendelian randomization studies, clinical studies, preclinical mechanistic evidence, and guidelines. Evidence was interpreted with attention to reverse causation, residual confounding, outcome definitions, and validation. Meta-analyses report a 25–34% higher PC risk among individuals with MetS, with a stepwise gradient across the number of metabolic components; hyperglycemia showed the strongest association among individual components (RR 1.55, 95% CI 1.42–1.70). However, MetS represents multiple versions of exposure, and the epidemiological and clinical evidence remains predominantly observational. Proposed mechanisms involving insulin signaling, adipokines, oxidative stress, epigenetic regulation, and the microbiome are largely preclinical and are not pancreas-specific. New-onset diabetes, rising HbA1c, and involuntary weight loss may mark occult pancreatic ductal adenocarcinoma, but available risk-enrichment models and biomarkers are insufficiently validated for routine screening. After diagnosis, metabolic status and body-composition measures have been associated with survival and perioperative outcomes, although confounding and cancer-related cachexia complicate interpretation. MetS is consistently associated with PC risk but is neither a single causal exposure nor an established target for PC prevention. MetS alone does not justify pancreatic imaging or biomarker testing. Lifestyle and pharmacologic treatment should follow established cardiometabolic indications; their effects on PC incidence remain unproven. Priorities include component-specific causal studies and prospective validation of risk-enrichment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, 4th Medical Discipline, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania.
- Department of Gastroenterology, Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", 400394 Cluj-Napoca, Romania.
- Department of Medical Biochemistry, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
ORCID-Profile: Vlad Dumitru Brata, Ioana Dobrotă, Teodora-Gabriela Alexescu, Mircea-Vasile Milaciu, Mirela-Georgiana Perne, Cezara-Andreea Gerdanovics, Lucia Maria Procopciuc, Angela Cozma, Olga-Hilda Orășan
Zitieren
APA
Borbei, R., Brata, V. D., Dobrotă, I., Ceteraș, L. M., Clim, M., Alexescu, T. G., Milaciu, M. V., Perne, M. G., Gerdanovics, C. A., Procopciuc, L. M., Cozma, A., & Orășan, O. H. (2026). Metabolic Syndrome and Pancreatic Cancer: Linking Insulin Resistance, Inflammation, and Carcinogenesis. Diagnostics, 16(16), 2616. https://doi.org/10.3390/diagnostics16162616
Vancouver
Borbei R, Brata VD, Dobrotă I, Ceteraș LM, Clim M, Alexescu TG, et al. Metabolic Syndrome and Pancreatic Cancer: Linking Insulin Resistance, Inflammation, and Carcinogenesis. Diagnostics. 2026;16(16):2616. doi:10.3390/diagnostics16162616
BibTeX
@article{Borbei2026,
author = {Borbei, Rahela and Brata, Vlad Dumitru and Dobrotă, Ioana and Ceteraș, Ligia-Maria and Clim, Mihai and Alexescu, Teodora-Gabriela and Milaciu, Mircea-Vasile and Perne, Mirela-Georgiana and Gerdanovics, Cezara-Andreea and Procopciuc, Lucia Maria and Cozma, Angela and Orășan, Olga-Hilda},
title = {Metabolic Syndrome and Pancreatic Cancer: Linking Insulin Resistance, Inflammation, and Carcinogenesis},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {16},
pages = {2616},
doi = {10.3390/diagnostics16162616}
}
EUVIMED